BACKGROUND AND PURPOSE: PPARβ enhances insulin sensitivity in adipocytes and skeletal muscle cells, but its effects on insulin signalling in endothelial cells are not known. We analysed the effects of the PPARβ/δ (PPARβ) agonists, GW0742 and L165041, on impaired insulin signalling induced by high glucose in HUVECs and aortic and mesenteric arteries from diabetic rats. EXPERIMENTAL APPROACH: Insulin-stimulated NO production, Akt-Ser(473) and eNOS-Ser(1177) phosphorylation, and reactive oxygen species (ROS) production were studied in HUVECs incubated in low- or high-glucose medium. Insulin-stimulated relaxations and protein phosphorylation in vessels from streptozotocin (STZ)-induced diabetic rats were also analysed. KEY RESULTS: HUVECs incubated in high-glucose medium showed a significant reduction in insulin-stimulated production of NO. High glucose also reduced insulin-induced Akt-Ser(473) and eNOS-Ser(1177) phosphorylation, increased IRS-1-Ser(636) and ERK1/2-Thr(183) -Tyr(185) phosphorylation and increased ROS production. The co-incubation with the PPARβ agonists GW0742 or L165041 prevented all these effects induced by high glucose. In turn, the effects induced by the agonists were suppressed when HUVEC were also incubated with the PPARβ antagonist GSK0660, the pyruvate dehydrogenase kinase (PDK)4 inhibitor dichloroacetate or after knockdown of both PPARβ and PDK4 with siRNA. The ERK1/2 inhibitor PD98059, ROS scavenger catalase, inhibitor of complex II thenoyltrifluoroacetone or uncoupler of oxidative phosphorylation, carbonyl cyanide m-chlorophenylhydrazone, also prevented glucose-induced insulin resistance. In STZ diabetic rats, oral GW0742 also improved insulin signalling and the impaired NO-mediated vascular relaxation. CONCLUSION AND IMPLICATIONS: PPARβ activation in vitro and in vivo restores the endothelial function, preserving the insulin-Akt-eNOS pathway impaired by high glucose, at least in part, through PDK4 activation.
BACKGROUND AND PURPOSE: PPARβ enhances insulin sensitivity in adipocytes and skeletal muscle cells, but its effects on insulin signalling in endothelial cells are not known. We analysed the effects of the PPARβ/δ (PPARβ) agonists, GW0742 and L165041, on impaired insulin signalling induced by high glucose in HUVECs and aortic and mesenteric arteries from diabeticrats. EXPERIMENTAL APPROACH: Insulin-stimulated NO production, Akt-Ser(473) and eNOS-Ser(1177) phosphorylation, and reactive oxygen species (ROS) production were studied in HUVECs incubated in low- or high-glucose medium. Insulin-stimulated relaxations and protein phosphorylation in vessels from streptozotocin (STZ)-induced diabeticrats were also analysed. KEY RESULTS: HUVECs incubated in high-glucose medium showed a significant reduction in insulin-stimulated production of NO. High glucose also reduced insulin-induced Akt-Ser(473) and eNOS-Ser(1177) phosphorylation, increased IRS-1-Ser(636) and ERK1/2-Thr(183) -Tyr(185) phosphorylation and increased ROS production. The co-incubation with the PPARβ agonists GW0742 or L165041 prevented all these effects induced by high glucose. In turn, the effects induced by the agonists were suppressed when HUVEC were also incubated with the PPARβ antagonist GSK0660, the pyruvate dehydrogenase kinase (PDK)4 inhibitor dichloroacetate or after knockdown of both PPARβ and PDK4 with siRNA. The ERK1/2 inhibitor PD98059, ROS scavenger catalase, inhibitor of complex II thenoyltrifluoroacetone or uncoupler of oxidative phosphorylation, carbonyl cyanide m-chlorophenylhydrazone, also prevented glucose-induced insulin resistance. In STZdiabeticrats, oral GW0742 also improved insulin signalling and the impaired NO-mediated vascular relaxation. CONCLUSION AND IMPLICATIONS: PPARβ activation in vitro and in vivo restores the endothelial function, preserving the insulin-Akt-eNOS pathway impaired by high glucose, at least in part, through PDK4 activation.
Authors: Tomas Fritz; David K Krämer; Håkan K R Karlsson; Dana Galuska; Peter Engfeldt; Juleen R Zierath; Anna Krook Journal: Diabetes Metab Res Rev Date: 2006 Nov-Dec Impact factor: 4.876
Authors: Francis Kim; Kelly A Tysseling; Julie Rice; Byron Gallis; Lutfiyah Haji; Cecilia M Giachelli; Elaine W Raines; Marshall A Corson; Michael W Schwartz Journal: J Mol Cell Cardiol Date: 2005-08 Impact factor: 5.000
Authors: B Brunmair; K Staniek; J Dörig; Z Szöcs; K Stadlbauer; V Marian; F Gras; C Anderwald; H Nohl; W Waldhäusl; C Fürnsinn Journal: Diabetologia Date: 2006-09-08 Impact factor: 10.122
Authors: David Kitz Krämer; Lubna Al-Khalili; Bruno Guigas; Ying Leng; Pablo M Garcia-Roves; Anna Krook Journal: J Biol Chem Date: 2007-05-11 Impact factor: 5.157
Authors: Ayman M Mahmoud; Fiona L Wilkinson; Eoghan M McCarthy; Daniel Moreno-Martinez; Alexander Langford-Smith; Miguel Romero; Juan Duarte; M Yvonne Alexander Journal: FASEB J Date: 2017-07-07 Impact factor: 5.191
Authors: Marta Toral; Rosario Jiménez; Miguel Romero; Iñaki Robles-Vera; Manuel Sánchez; Mercedes Salaices; José Mario Sabio; Juan Duarte Journal: Arthritis Res Ther Date: 2017-12-06 Impact factor: 5.606
Authors: Rosario Jimenez; Marta Toral; Manuel Gómez-Guzmán; Miguel Romero; Manuel Sanchez; Ayman M Mahmoud; Juan Duarte Journal: Oxid Med Cell Longev Date: 2018-06-25 Impact factor: 6.543